Zhitong Finance App News, Osecon (002755.SZ) issued an announcement. Jiangsu Aosaikang Biomedical Co., Ltd., a subsidiary of the company, recently received the “Notice of Acceptance” issued by the State Drug Administration, and the application for registration and marketing license for domestically produced drugs of the company's innovative drug olmetotazumab was accepted.

Ometotazumab injection, commonly known as Omectatug in English; olmetotamab injection in combination with CAPOX (fluorouracil and platinum drugs) and tirelizumab has reached the primary end point of progression-free survival (PFS) assessed by the Independent Review Committee (IRC) in the primary treatment of patients with CLDN18.2 positive, unresectable locally advanced, recurrent, or metastatic gastric and esophagal-gastric junction adenocarcinoma.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.